Prevención primaria con aspirina en la hipertensión arterial

Referencias bibliográficas

• Hennekens, CH,Dyken, ML,Fuster, V. (1997). Aspirin as a therapeutic agent in Cardiovascular Disease. A statement for Healthcare Proffesionals from the American Heart association. Circulation. 96. 2751-2753
• Awtry, EH,Loscalzo, J. (2000). Aspirin. Circulation. 101. 1206-1218
• Steer, KA,Wallace, TM,Bolton, CH,Hartog, M. (1997). Aspirin protects low density lipoprotein from oxidative modification. Heart. 77. 333-337
• Husain, S,Andrews, NP,Mulcahy, D,Panza, JA,Quyyumi, AA. (1998). Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 97. 716-720
• Peto, R,Gray, R,Collins, R. (1988). Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 296. 313-316
• (1989). The Steering Committee on the Physicians Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 321. 129-135
• (1998). The Medical Research Council's General Practice Research Framework Thrombosis prevention trial: randomised trial of low intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 351. 233-241
• Hansson, L,Zanchetti, A,Curruthers, SG. (1998). Effects of intensiva blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Lancet. 351. 1755-1762
• Ramsay, LE,Williams, B,Johnston, D. (1999). British Hypertension Society guidelines for hypertension management 1999: summary. BMJ. 319. 630-635
• Meade, TW,Mellows, S,Brozovic, M. (1986). Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 11. 533-537
• Cairns, JA,Theroux, P,Lewis, DH,Ezekowitz, M,Meade, TW. (2001). Antithrombotic agents in Coronary artery disease. CHEST. 119. 2285
• Boissel, JP. (1998). Individualising aspirin therapy for prevention of cardiovascular events. JAMA. 280. 1949-1950
• He, J,Wheiton, PK,Vu, B,Klay, MJ. (1998). Aspirin and risk of haemorrhagic stroke. A meta-analysis of randomised controlled tdals. JAMA. 280. 1930-1935
• Sanmuganathan, PS,Ghahramani, P,Jackson, PR,Wallis, EJ,Ramsay, LE. (2001). Aspirin for primary prevention of coronary heart disease: safety and absoluta benefit relatad to coronary risk derived from meta-analysis of randomised trials. Heart. 85. 65-271
• Wallis, EJ,Ramsay, LE,UI, I,Ghahramani, P,Jackson, PR,Rowland, K,Yeo, WW. (2000). Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ. 320. 671-676
• (2001). Collaborative group of the Primary prevention Project lowdose aspirin and Vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 357. 89-95
• Hayden, M,Pignone, M,Phillips, C,Muirow, C. (2002). Aspirin for the primary Prevention of Cardiovascular Events: A Summary of the evidence for the U.S. preventiva services task force. Ann lntern Med. 136. 161-172
• (2002). Antithrombotic Trialists' Collaboration Collaborative metaanalysis of randomised tríals of antiplatelet therapy for prevention of death, myocardial infactíon, and stroke in high risk patients. BMJ. 324. 71-86
• Rosser, WW. (2001). Aspirin for primary prevention of cardiovascular events. Lancet. 357. 84-85
• Meade, TW,Brennan, PJ. (2000). Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ. 321. 13-17
• Manson, JE,Stampfer, J,Colditz, GA. (1991). A prospective study of aspirin use and primary prevention in cardiovascular disease in women. JAMA. 266. 521-527
• Rexrode, KM,Lee, IM,Cook, NR,Henekens, CH,Buring, JE. (2000). Baseline characteristics of participants in the Women's Health Study. J Women's Health Gend-Based Med. 9. 19-27